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A B S T R A C T
Background: The Orsiro is a hybrid stent which has passive (amorphous silicon carbide) and active 
(poly-L-lactic acid, PLLA) coatings. The first layer encapsulates the stent struts, promoting lower local 
inflammation, whereas the second layer releases sirolimus through a biodegradable matrix. This study’s 
aim was to compare the results of percutaneous coronary interventions (PCI) with Orsiro and Xience™ V 
stents (everolimus-eluting stent) in daily clinical practice. 
Methods: Observational study in which patients were divided into two groups: those who received only 
one or more Orsiro stents, and those who received only XienceTM V stents. Early and late outcomes were 
prospectively collected. 
Results: Between September 2012 and March 2014, this study included 92 and 108 patients treated with Orsiro 
and Xience™ V stents, respectively. Clinical, angiographic, and procedure characteristics were mostly similar 
between groups. Rates of procedure success (98.9% vs. 95.4%; p = 0.22), in-hospital mortality (1.1% vs. 0%; p = 0.40) 
and stent thrombosis (0% vs. 0.9%, p = 0.30) did not differ between groups. Time of follow-up was 434 ± 111 and 
477 ± 66 days (p = 0.23), respectively, and differences in mortality (0.9% vs. 0%, p = 0.30), stent thrombosis (0% vs. 
0.9%; p = 0.30), or need for repeat revascularization of the target lesion (0% vs. 0.9%; p = 0.30) were not observed.
Conclusions: Orsiro and Xience™ V stents showed similar performance, with low rates of early and late 
clinical and angiographic events.
© 2015 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Published by Elsevier Editora Ltda. 
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 
 
Resultados iniciais e tardios de pacientes tratados com stent híbrido eluidor de 
sirolimus ou stent eluidor de everolimus 
R E S U M O
Introdução: O stent Orsiro é um stent híbrido que possui revestimentos passivo (carbeto de silício amorfo) 
e ativo (ácido poli-L-lático, PLLA). O primeiro encapsula as hastes do stent, promovendo menor inflamação 
local, e o segundo libera o sirolimus por meio de matriz biodegradável. Nosso objetivo foi comparar os 
resultados das intervenções coronárias percutâneas (ICP) dos stents Orsiro e Xience® V (eluidor de 
everolimus) na prática clínica diária. 
Métodos: Estudo observacional em que os pacientes foram alocados em dois grupos: os que receberam 
exclusivamente um ou mais stents Orsiro e os que receberam exclusivamente stents Xience® V. Desfechos 
iniciais e tardios foram prospectivamente coletados. 
Resultados: Entre setembro de 2012 e março de 2014, incluímos 92 e 108 pacientes tratados com stent 
Orsiro e Xience® V, respectivamente. Características clínicas, angiográficas e do procedimento foram, em 
sua maioria, semelhantes entre os grupos. As taxas de sucesso do procedimento (98,9% vs. 95,4%; p = 0,22), 
mortalidade (1,1% vs. 0%; p = 0,40) e trombose do stent (0% vs. 0,9%; p = 0,30) hospitalares não diferiram 
entre os grupos. O tempo de seguimento foi de 434 ± 111 e 477 ± 66 dias (p = 0,23), respectivamente, não 
sendo observadas diferenças na mortalidade (0,9% vs. 0%; p = 0,30), trombose do stent (0% vs. 0,9%; p = 0,30) 
e nem na necessidade de revascularização da lesão alvo (0% vs. 0,9%; p = 0,30). 
Conclusões: Os stents Orsiro e Xience® V apresentaram desempenho semelhante, com baixas taxas de 
eventos clínicos e angiográficos iniciais e tardios.
© 2015 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Publicado por Elsevier Editora Ltda. 
Este é um artigo Open Access sob a licença de CC BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
The use of drug-eluting stents (DES) represented a major step fo-
rward in current interventional cardiology, as it has significantly 
reduced restenosis rates1 and the need for repeat revascularization.2 
How-ever, some specific issues, such as late thrombosis3 and local 
inflammatory response,4,5 have promoted significant advances in 
the development of prostheses, to allow better stent performance 
associated with greater patient safety.
DES consist of a platform, a polymer, and an antiproliferative 
drug.6 Bioengineering of materials has improved stent components, 
resulting in changes in the polymers and the use of several antipro-
liferative drugs. The Orsiro stent (Biotronik AG, Bulach, Switzerland), 
a hybrid sirolimus-eluting stent, is currently available for clinical 
use, but its utilization in Brazil is scarcely known.
The aim of this study was to evaluate early and late outcomes 
of patients from daily clinical practice submitted to percutaneous 
coronary intervention (PCI) with Orsiro stents, and to compare 
them to those receiving the Xience™ V stent (Abbott Vascular, 
Santa Clara, USA).
Methods
Design
This was an observational study with prospective data collection.
Sample selection
Patients undergoing PCI for the treatment of ischemic heart dise-
ase in the CINECORS service of the Centro de Cardiologia do Hospital 
Ernesto Dornelles, in Porto Alegre (RS), Brazil were assessed. Varia-
bles related to risk factors for cardiovascular disease, procedure in-
dication, technical details of the intervention, complications, and 
in-hospital and late follow-up were prospectively recorded on a spe-
cific form and entered in a dedicated database. For comparison, pa-
tients were divided into two groups: patients who received only 
Orsiro stents and patients who received only Xience™ V stents. All 
patients signed the free and informed consent form.
Percutaneous coronary intervention
The PCIs were carried out according to standard techniques and 
following the current guidelines,7 through femoral or radial access. 
Lesion assessment was performed by quantitative angiographic 
analysis, after intracoronary nitrate administration. Lesions were 
classified according to the definition of the American College of 
Cardiology/American Heart Association (A, B1, B2 and C).8 Pre- and 
post-dilation were used at the interventionist’s discretion. All pa-
tients received unfractionated heparin at the begining of the pro-
cedure (70 to 100 U/kg), with additional doses administered if 
required, to maintain an activated clotting time (ACT) from 250 to 
350 seconds. Dual antiplatelet therapy was used in all patients 
with the administration of aspirin, 75 to 200 mg a day, together 
with a P2Y12 inhibitor (clopidogrel, prasugrel or ticagrelor).
Orsiro stent description 
The Orsiro stent (Registered with the Brazilian National Health 
Surveillance Agency [Agência Nacional de Vigilância Sanitária - 
ANVISA] No. 80224390190) has a PRO-Kinetic Energy stent pla-
tform (L605 Chromium Cobalt alloy with 60 m thick struts). It is 
considered a hybrid stent, because it has two coatings: a passive 
(PROBIO - amorphous silicon carbide coating) and an active coating 
(BIOlute - poly-L-lactic acid, PLLA). The passive PROBIO coating en-
capsulates the stent struts and reduces the interaction between 
metal and the tissue. Consequently, it promotes less local in-
flammation. The BIOlute active coating contains a highly biocom-
pat ible poly mer t hat  releases si rol imus dr ug t hrough a 
biodegradable matrix for 12 to 14 weeks. The BIOlute polymer is 
slowly degraded into carbon dioxide and water. After complete 
polymer degradation, only the PRO-Kinetic Energy stent remains 
(Fig. 1).
Figure 1. The Orsiro™ stent.
Clinical follow-up and outcomes
Patients were clinically followed during the hospital stay and later 
through clinical consultation, chart review, and/or telephone contact. 
The following were defined as hospital outcomes for the analysis: pro-
cedure success rate (stent implantation with residual lesion < 10% and 
Thrombolysis in Myocardial Infarction [TIMI] 3 flow after the proce-
dure), hospital mortality, stent thrombosis, bleeding assessed by the 
GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) 
study criteria, contrast-induced nephropathy (50% increase over base-
line serum creatinine), or need for dialysis. As for the late follow-up, 
the following were evaluated as outcomes: mortality, stent thrombo-
sis, and symptom-guided target-lesion revascularization.
Statistical analysis
The variables are shown in percentages, as mean ± standard de-
viation (SD). For comparison between groups, the Chi-squared test 
or Student’s t-test were used for categorical or continuous variables, 
respectively. The Mann-Whitney test was used for variables with 
normal distribution. A two-tailed p-value of < 0.05 was considered 
statistically significant. All data were analyzed using Statistical Pa-
ckage for the Social Science (SPSS) for Windows, version 18.0 (SPSS, 
Chicago, USA).
Results
Between September 2012 and March 2014, a total of 367 PCIs 
were performed in this service. After the inclusion criteria were 
applied, two groups of 92 and 108 patients participated in the study, 
treated exclusively with Orsiro and Xience™ V stents, respectively. 
As shown in Table 1, it was observed that both groups showed no 
differences in risk factors for cardiovascular disease, medications, 
and clinical indication for the procedure.
A total of 95 and 114 lesions were treated, respectively, in patients 
using Orsiro and Xience™ V stents. Vessel diameter (3.0 mm ± 0.2 vs. 3.0 
± 0.3 mm; p = 0.51) and mean lesion length (18.0 ± 6 mm vs. 20.0 ± 7 mm; 
p = 0.08) were equivalent in both groups. The numbers of Orsiro and 
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Xience™ V stents per patient were 1.3 ± 0.56 and 1.4 ± 0.55 (p = 0.60). A 
total of 91 and 103 patients from the Orsiro and Xience™ V groups (98.9% 
vs. 95.4%; p = 0.22) were successfully treated, respectively. Table 2 descri-
bes the main angiographic and procedure characteristics.
During the in-hospital follow-up, no differences were observed be-
tween the groups regarding mortality, development of stent throm-
bosis, bleeding or contrast nephropathy (Table 3). One patient from 
the Orsiro group died due to cardiogenic shock during acute myocar-
dial infarction. The only case of acute thrombosis occurred with a 
Xience™ V stent, caused by prosthesis underexpansion. There was a 
slight tendency to increased need for dialysis in the Orsiro group, al-
though this finding has no direct link to the type of stent used.  
Late follow-up was available for all 92 (100%) patients from the 
Orsiro group and the 104 (96,2%) patients of the Xience™ group. 
Mean follow-up was 434 ± 111 and 477 ± 66 days, respectively (p = 
0.23). There was one death (0.9%) in the Orsiro group from complica-
tions related to cirrhosis at 177 days of follow-up. In the Xience™ 
group, on the 90th day post-stenting, there was a case of late stent 
thrombosis (0.9%) due to dual antiplatelet therapy interruption. A 
case of target-lesion revascularization (0.9%, corresponding to one 
patient submitted to the implantation of 2 stents with the mini-
-crush technique) was also observed at 232 days of follow-up.
Discussion
This study showed that the new hybrid sirolimus-eluting Orsiro 
stent showed excellent immediate results and sustained benefit at 
the late follow-up when compared to the everolimus-eluting Xien-
ce™ V stent.
The BIOFLOW-I study9 evaluated the first patients treated with the 
Orsiro stent in clinical practice. In that study, 30 patients were treated 
with the sirolimus-eluting biodegradable polymer stent. Similarly to 
the present study, there were no cases of late thrombosis. In the BIO-
FLOW-I study, however, angiographic follow-up with intravascular 
ultrasound was part of the protocol. Due to this characteristic, a bet-
ter evaluation of the device was performed. There were no cases of 
binary restenosis. However, the procedures’ low complexity favored 
the excellent early and late outcomes in both studies. 
The in-hospital clinical evolution was equivalent in the two 
groups of the present study. The only case of thrombosis in the Xien-
ce™ V group was due to an underexpanded stent. The consensus is 
that cases of thrombosis within the first days are usually due to the 
implantation technique.10 In the Orsiro group, the event of death was 
explained by the evolution of cardiogenic shock. There was a higher 
rate of contrast-induced nephropathy with the need for dialysis in 
the sirolimus-eluting stent group. Although this finding is not asso-
ciated with the stent type, the higher prevalence of insulin-depen-
dent diabetes in this group can justify what occurred.
Late follow-up was favorable for both the Orsiro and the Xience™ 
stents. Mortality in the Orsiro group was not due to cardiovascular 
causes. The two events related to the target-lesion in the Xience™ 
group (one late thrombosis and one restenosis) were justified by 
poor adherence to dual antiplatelet therapy and complex interven-
tion with two stents. The low rate of clinical events is noteworthy in 
the present study. In the BIOFLOW-I and -II studies,11 the target-le-
sion revascularization rates were around 6.7% and 2.7%, respectively. 
However, the included patients had a low rate of complex interven-
tions (87% single-vessel PCI), 3-mm vessel caliber, and lesion length 
of approximately 20 mm. Additionally, the mean SYNTAX score of 10 
Table 1
Clinical characteristics.
Variable Orsiro stent (n = 92) Xience™ V stent (n = 108) p-value
Age, years 66.4 ± 9.8 65.6 ± 10.3 0.59
Male gender, n (%) 58 (63) 70 (64.8) 0.88
Weight, kg 75.1 ± 14 78.7 ± 18 0.11
Height, cm 166.0 ± 8.8 168.8 ± 9.3 0.81
White, n (%) 82 (89.1) 100 (92.6) 0.46
Active smoking, n (%) 16 (17.4) 16 (14.8) 0.38
Arterial hypertension, n (%) 84 (91.3) 97(89.8) 0.81
Diabetes mellitus, n (%) 44 (47.8) 48 (52.2) 0.43
Dyslipidemia, n (%) 53 (57.6) 59 (54.6) 0.39
Family history of CAD, n (%) 9 (9.8) 9 (8.3) 0.45
Prior PCI, n (%) 32 (34.8) 48 (44.4) 0.10
Prior CABG, n (%) 14 (15.2) 15 (13.9) 0.84
Previous AMI, n (%) 15 (16.3) 20 (18.5) 0.71
Previous stroke, n (%) 5 (5.4) 4 (3.7) 0.73
Clinical presentation, n (%) 0.45
Stable angina 73 (79.3) 83 (76.9)
ACS without ST elevation 17 (18.5) 19 (17.6)
ACS with ST elevation 2 (5.4) 6 (5.6)
Medications, n (%)
Acetylsalicylic acid 90 (97.8) 108 (100) 0.21
P2Y12 inhibitors 0.55
Clopidogrel 88 (95.7) 100 (92.6)
Prasugrel/ ticagrelor 4 (4.3) 8 (7.4)
Beta-blocker 67 (72.8) 81 (75) 0.74
ACEI 34 (37) 27 (25) 0.09
Diuretics 14 (15.2) 14 (13) 0.68
ARB 16 (17.4) 27 (25) 0.22
Nitrates 22 (23.9) 19 (17.6) 0.29
Calcium antagonists 3 (3.3) 6 (5.6) 0.51
Statins 56 (60.9) 72 (66.7) 0.46
Oral antidiabetics 20 (21.7) 34 (31.5) 0.15
Insulin 24 (26.1) 16 (14.8) 0.05
CAD: coronary artery disease; PCI: percutaneous coronary intervention; CABG: coronary artery bypass surgery; AMI: acute myocardial infarction; ACS: acute coronary syndrome; ACEI: angiotensin converting 
enzyme inhibitor; ARB: angiotensin II receptors blockers.
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Table 2
Angiographic and procedure characteristics.
Variable Orsiro stent (n = 92) Xience™ V stent (n = 108) p-value
Access route, n (%) 0.50
Radial 37 (40.2) 35 (32.4)
Femoral 54 (58.7) 72 (66.7)
Brachial 1 (1.1) 1 (0.9)
Intervention type, n (%) 0.25
Single vessel 80 (87) 87 (80.6)
Multivessel 12 (13) 21 (19.4)
Culprit vessel, n (%) 0.94
Left anterior descending artery 41 (43.2) 49 (43.0)
Right coronary artery 27 (28.4) 31 (27.2)
Left circumflex artery 16 (16.8) 21 (18.4)
Left main coronary artery 3 (3.2) 3 (2.6)
Secondary branches 6 (6.3) 6 (5.3)
Saphenous vein graft 2 (2.1) 3 (2.6)
Mammary graft 0 1 (0.9)
Bifurcation lesion, n (%) 16 (17.4) 16 (14.8) 0.70
Chronic occlusion, n (%) 3 (3.3) 6 (5.6) 0.51
Calcified lesion, n (%) 42 (45.7) 45 (41.7) 0.66
Lesion type, n (%) 0.30
A 0 3 (2.7)
B1 15 (15.9) 13 (11.4)
B2 28 (29.4) 30 (26.3)
C 52 (54.7) 68 (59.6)
SYNTAX score 10.6 ± 7.5 11.0 ± 7.7 0.74
Stenosis diameter pre, % 90.5 ± 8.1 90.3 ± 8.1 0.85
Stenosis diameter post, % 1.0 ± 2.5 3.7 ± 13.8 0.30
Pre-dilation, n (%) 87 (94.6) 98 (90.7) 0.42
Post-dilation, n (%) 61 (66.3) 85 (78.7) 0.05
Stent diameter, mm 3.0 ± 0.2 3.2 ± 0.4 0.03
Stent length, mm 18.5 ± 6.4 25.0 ± 8.5 < 0.001
Stent implantation pressure (atm) 16.1 ± 3.1 16.3 ± 3.6 0.63
Table 3
In-hospital complications.
Variable Orsiro Stent (n = 92) Xience™ V Stent (n = 108) p-value
Mortality, n (%) 1 (1.1) 0 0.40
Stent thrombosis, n (%) 0 1 (0.9) 0.30
GUSTO bleeding, n (%) 0.48
Mild 91 (98.9) 105 (97.2)
Moderate 1 (1.1) 2 (1.9)
Severe 0 1 (0.9)
Contrast-induced nephropathy, n (%) 9 (9.8) 13 (12) 0.60
In-hospital dialysis, n (%) 2 (2.2) 0 0.09
GUSTO: Global Use of Strategies to Open Occluded Coronary Arteries study.
is consistent with low complexity interventions. Considering these 
characteristics, the absence of clinical restenosis in the present stu-
dy can be explained.
This study has the following limitations: it was a single-center 
study with a limited number of patients, and patients were followed 
only through clinical follow-up. Therefore, no comments regarding 
the angiographic performance of stents can be made. However, the-
se data reflect the real-world experience, in which patients are re-
ferred to angiography when symptoms are present.
Conclusions
In this clinical practice study, both the Orsiro (sirolimus-eluting) 
and Xience™ V (everolimus-eluting) stents showed similar perfor-
mance, with low clinical event rates at the early and late follow-up.
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